Phil Darcy
Professor Phil Darcy is a NHMRC Principal Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. Phil received his PhD in 1994 and undertook postdoctoral studies at the Austin Research Institute prior to relocating to the Peter MacCallum in 2000. Since this time his work has focused on developing novel T cell based immunotherapy approaches for cancer in preclinical mouse models and translating this into patients. Over the past 20 years he has shown that adoptive transfer of gene-engineered mouse and human T cells expressing chimeric antigen receptors (CARs) could effectively eradicate cancer in mice. A Phase I clinical trial leading from this work was recently completed at the Peter MacCallum Cancer Centre in patients with acute myeloid leukaemia that represented a first in Australia using this approach with another ongoing CAR T cell trial in solid cancers. More recently his studies have involved combining gene-engineered T cells with other immune based therapies including checkpoint blockade which is showing tremendous promise in preclinical models and patients. Phil has received tremendous support from numerous national and international funding bodies and industry and has consistently published his work in premier scientific journals.
Abstracts this author is presenting: